[Annual updates of pulmonary infectious diseases in 2023]

Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):141-146. doi: 10.3760/cma.j.cn112147-20231117-00317.
[Article in Chinese]

Abstract

In 2023, a range of pulmonary infectious diseases remain a significant public health concern. Meanwhile, the growing problem of antibiotic resistance, rising tuberculosis cases with lagging control measures, and increased susceptibility to fungal pneumonia after viral infections, have complicated the diagnosis and treatment of respiratory infectious diseases. Despite these challenges, the year saw several significant research achievements in this field. Key advances include a deeper understanding of disease pathogenesis, improvements in pathogen detection technologies, the development of innovative antiviral and antibacterial drugs, progress in vaccine research, and advances in pulmonary rehabilitation methods. This review provided a concise summary of these key findings in 2023, with the aim of providing insights for future research and healthcare initiatives.

2023年,各类肺部感染性疾病仍在危害人群生命健康。呼吸感染性疾病的诊治面临诸多挑战,包括肺炎常见病原菌的耐药性持续增加、结核病的发病率上升且防治进程放缓、病毒流行导致真菌感染性疾病增加等。过去一年,在致病机制认识、检测技术革新、新型抗菌与抗病毒药物的开发、疫苗的基础与临床研究、预防和康复手段等领域有众多重磅研究成果发表。本文详细回顾和总结了呼吸感染性疾病领域在2023年度发表的重要研究成果,为未来的研究和实践提供参考。.

Publication types

  • Review
  • English Abstract

MeSH terms

  • Communicable Diseases*
  • Humans
  • Influenza, Human*
  • Mycoses*
  • Tuberculosis*
  • Virus Diseases*